Brent Morse, M.S., is a principal consultant at Dark Horse Consulting Group with more than 20 years of experience in the biotech industry, including eight years of experience in cell and gene therapy. At Dark Horse, Brent's areas of focus include analytical development, process development, external manufacturing, and CMC strategy. Before joining Dark Horse, Brent most recently served as Vice President of Process and Analytical Development at Vor Biopharma, a biotechnology company developing autologous genome-edited hematopoietic stem cell and chimeric antigen receptor T (CAR-T) products for hematological malignancies. Earlier in his career, Brent led analytical development at CRISPR Therapeutics, where he was responsible for developing CRISPR’s overall analytical strategy and overseeing external gene editing reagent manufacture supporting both the gene-edited hematopoietic stem cell and allogeneic CAR-T products. Brent’s team supported multiple regulatory filings, including for Casgevy, the world's first approved CRISPR based medicine.